Enforcing German Pharmaceutical Patents Against Imports From China in 2026: a Step-by-step Guide

Pharmaceutical patent enforcement germany has become a defining concern for rights holders confronting China-origin drug imports entering the German market in 2026. Cross-border trade volumes, tighter pharmaceutical supply chains and a persistent pattern of patent disputes have combined to make border interception and rapid civil relief central tactical priorities. This guide sets out, in operational sequence, how in-house counsel and IP managers can move from suspicion to seizure, covering evidence packages, customs detention under EU law, preliminary injunctions and full infringement litigation. It is written for decision-makers who need a procedural playbook, not a trend summary.

Overview, why imports from China are a priority in 2026

The commercial risk profile for patented pharmaceuticals sourced from Chinese manufacturers has sharpened. Enforcement practice increasingly emphasises customs measures and pre-litigation evidence gathering. For patent holders, the practical question is often no longer whether infringing imports arrive, but how quickly and decisively they can be stopped at or shortly after the border.

Effective pharmaceutical patent enforcement germany can depend on treating the border as an early line of defence and the courts as the enforcement engine. The available measures, customs detention, preliminary injunctions and civil seizure, are complementary rather than alternative, and the strongest outcomes often come from deploying them in coordination. A shipment detained at customs buys time; an injunction converts that time into a binding prohibition; civil seizure removes the goods from circulation.

Key enforcement goals: stop supply, secure damages, disrupt the source

Three objectives should drive every enforcement decision. First, stop the supply, prevent infringing product from reaching distributors, pharmacies and patients. Second, secure damages, preserve the evidence and financial trail needed to quantify and recover loss. Third, disrupt the source, trace the Chinese manufacturer or exporter so that future shipments can be intercepted and, where possible, the upstream trade can be curtailed.

How can a pharma company stop infringing medicines being imported into Germany from China? In short: combine targeted evidence collection, customs registration and detention under Regulation (EU) No 608/2013, and an urgent German preliminary injunction, followed by civil seizure and, where necessary, full trial. The step-by-step section below explains how to execute each stage.

Eligibility, when German patents can be enforced against imports

Before mobilising resources, confirm that the patent right can actually be enforced against the specific import. Enforceability turns on territoriality, the scope of the claims and, critically for pharmaceuticals, the exhaustion doctrine.

Territorial scope and importation

Patent rights are territorial. A German national patent, or a European patent validated for Germany, confers protection within German territory. (Where a European patent with unitary effect applies, enforcement may instead fall within the jurisdiction of the Unified Patent Court, a point to check for the specific right asserted.) Under the German Patent Act (Patentgesetz), the importation of a patented product without the proprietor’s consent is an infringing act. This means that a Chinese-manufactured drug covered by a valid German patent claim becomes actionable at the point it is imported into or offered for sale in Germany, the manufacturer’s location abroad does not shield the importer, distributor or offeror operating inside the jurisdiction.

What counts as an infringing import includes not only physical bringing-in of the goods but also related acts of offering, placing on the market, using or stocking for those purposes. Identifying the correct defendant, importer of record, logistics intermediary, distributor or online seller, is a threshold task that shapes the entire enforcement strategy.

Parallel imports and exhaustion, when imports cannot be blocked

An important eligibility filter for pharmaceutical patent enforcement germany is the exhaustion of rights. Where a patented product has been placed on the market within the European Economic Area (EEA) by the patent holder or with the holder’s consent, the patent right in respect of that specific product is exhausted. The holder cannot then use the patent to block onward movement of those genuine goods, the classic parallel-import scenario.

The distinction that matters is between genuine goods legitimately marketed in the EEA (where patent-based enforcement will generally fail) and goods manufactured and imported from China without consent (where enforcement is available). Before any customs application or injunction request, verify the supply chain: where were the goods first placed on the market, and by whom? Misreading exhaustion is one of the most costly errors in import enforcement, because an injunction obtained against genuine parallel imports can expose the applicant to substantial wrongful-injunction damages.

Patent claim drafting tips relevant to import enforcement

Enforcement is generally easier where claims are drafted with importation in mind. Product claims covering the active pharmaceutical ingredient, the formulation and, where appropriate, the finished dosage form give a broad basis for stopping imports, because they attach to the physical article crossing the border. Purpose-limited or use claims can be harder to enforce against a customs authority that must make a rapid prima facie assessment from packaging and documentation. Where a portfolio permits, asserting a claim that maps directly onto an inspectable physical characteristic of the imported product streamlines both customs detention and court proceedings.

Step-by-step procedure for pharmaceutical patent enforcement germany

The following numbered playbook takes the enforcement action from internal investigation through to post-enforcement follow-up. Each step should be prepared in parallel where possible so that, once a shipment is identified, the response is immediate.

1. Internal investigation and evidence collection. Establish chain of custody, record batch numbers, secure product samples and trace the supplier. Engage local China counsel or investigators to link the goods to a specific manufacturer or exporter.
2. Customs application to German customs. File the Application for Action with the German customs administration (Zoll) under Regulation (EU) No 608/2013 so that customs can detain suspect consignments on identification.
3. Request for provisional measures to secure evidence. Where evidence at the border is at risk of loss, apply for provisional measures to preserve it, potentially on an ex parte basis.
4. File a preliminary injunction (einstweilige Verfügung). Apply to the competent German court for an urgent order prohibiting importation, distribution and sale.
5. Civil seizure and enforcement. Enforce the order through customs instruction or a bailiff (Gerichtsvollzieher) to physically remove the goods from circulation.
6. Main infringement litigation. Where the dispute is contested or a final remedy is required, pursue full proceedings on the merits.
7. Post-enforcement follow-up. Manage destruction or return of goods and pursue the damages claim.

Step 1, Internal investigation and evidence collection

Everything downstream depends on the quality of the evidence assembled here. Build a priority evidence list: retained product samples with documented chain of custody, batch and lot numbers, high-resolution photographs of packaging and labelling, and shipping documents. In parallel, instruct China-side investigators or counsel to trace the manufacturer through procurement records, purchase orders and correspondence. Establish a chain-of-custody log at the outset so that every sample and document remains admissible.

Step 2, Customs application (customs seizure pharmaceutical imports Germany)

Register the patent right with the German customs administration (Zoll) via its IPR-protection process. The Application for Action identifies the protected right, provides technical information enabling customs officers to recognise infringing goods, and appoints a contact for rapid liaison. Once registered, customs can detain suspect consignments and notify the holder. Accurate technical descriptions and correct product classification are important, customs act on the paperwork supplied, so a weak or vague application will be less likely to trigger detention.

Step 3, Securing evidence at the border

Where there is a risk that goods or documents will disappear before a court can act, measures under the German Code of Civil Procedure (Zivilprozessordnung), including an inspection/preservation order, can help preserve evidence. In pharmaceutical cases, securing a representative sample for independent laboratory analysis is often a pivotal step, because comparative composition testing frequently supplies strong proof of infringement.

Step 4, Preliminary injunction pharma Germany

The preliminary injunction (einstweilige Verfügung) is the fastest route to a binding prohibition. The applicant must show a prima facie case of infringement and urgency. German courts expect the applicant to move promptly once aware of the infringement; delay undermines the urgency requirement. The application is supported by patent documentation, evidence of product identity and infringement, proof of imminent or ongoing importation, and material setting out the urgency and the harm. In appropriate cases the court may proceed rapidly, and ex parte relief is possible where notice would defeat the purpose of the order.

Note that, following Court of Justice of the EU case law, German courts will generally assess the validity of the asserted patent when deciding on preliminary relief.

Step 5, Civil seizure and enforcement

An order is only as good as its enforcement. Civil seizure removes the physical goods from circulation, executed either through a customs instruction where the consignment is already detained, or through a court bailiff. Plan the logistics in advance: storage of pharmaceutical products carries handling, temperature-control and compliance obligations, and disposal is governed by health and environmental rules that must be observed.

Step 6, Main infringement litigation

A preliminary injunction is interim relief; a contested matter or a claim for a final remedy requires proceedings on the merits before the competent regional court (Landgericht). Germany operates a bifurcated system: infringement and validity are handled separately, with validity typically challenged before the Federal Patent Court (Bundespatentgericht) or, for European patents, through opposition/limitation at the European Patent Office. This stage establishes liability definitively and quantifies damages. It is the slowest phase but the one that delivers the durable outcome.

Step 7, Post-enforcement follow-up

Following a successful action, manage the destruction or return of seized goods in compliance with pharmaceutical disposal rules, and pursue the damages and account-of-profits claim. Preserve the full evidentiary record, it supports both the damages quantification and any future action against repeat shipments from the same source.

Step / Who / Duration timeline

Comparison: injunction vs customs detention vs civil seizure

Required documents and evidence for patent enforcement

Both customs applications and court proceedings stand or fall on documentation. The table below sets out the core items, why each is needed and where to obtain it. Two assets are worth preparing as standing templates: a customs application checklist for EU/German procedures and an evidence chain-of-custody template.

Evidence chain of custody for Chinese-origin goods

For imports traced to China, the evidentiary weak point is usually the link between the physical sample examined and the shipment or manufacturer alleged to have supplied it. Maintain an unbroken chain-of-custody log recording who collected each sample, when, from which consignment, and how it was stored and transferred to the testing laboratory. Where investigators operate on the ground in China, ensure their reports document sourcing precisely, so the connection between the exporter and the goods detained in Germany is defensible in court.

Pharmaceutical specifics, product samples, lab analysis and regulatory paperwork

Pharmaceuticals raise proof requirements that other product categories do not. Independent laboratory analysis of composition, and where relevant bioassay testing, often provides a decisive comparison between the patented product and the import. Retain representative samples under proper storage conditions, and gather any regulatory paperwork accompanying the goods, which can reveal both the claimed origin and discrepancies that support the infringement case.

Timeline and deadlines

Import enforcement runs on overlapping clocks. Under Regulation (EU) No 608/2013, once customs detain suspect goods the right holder must initiate proceedings within the statutory window, generally ten working days (extendable once in appropriate cases, and shorter for perishable goods), failing which the goods may be released. This deadline makes advance preparation of the injunction application essential: the customs detention and the court filing must be ready to move in lockstep.

Statutory clocks

The customs detention window under the EU regime is short and unforgiving, which is why the internal investigation and draft court papers should be substantially complete before a shipment is even detained. The Zivilprozessordnung governs the procedural framework for provisional measures and evidence preservation, and the urgency requirement for injunctions imposes its own practical deadline: act promptly on discovery of the infringement, because a court may refuse relief where the applicant has delayed.

Typical judicial timelines in 2026

In practice, a preliminary injunction can be secured within days to a few weeks depending on the court’s load and the strength of the evidence, with expedited handling available in clear cases. Main infringement proceedings before the regional courts commonly run for many months to around two years at first instance, subject to parallel validity proceedings and appeals. The Step / Who / Duration table above cross-references these durations against each stage.

Costs and fees

Budgeting realistically is part of enforcement strategy, because security requirements and investigation costs can be substantial. The ranges below are indicative only and vary significantly with complexity, claim value, court region and the depth of investigation required; obtain a case-specific estimate from counsel. Note that statutory court and lawyer fees in Germany are based on the value in dispute under the applicable fee legislation, and the losing party generally bears the reimbursable statutory costs of the successful party.

Funding strategies

Any bond or security a court may require to grant an injunction can be a significant cash item and should be planned for before filing. Consider cost-sharing arrangements where several rights holders face the same source, staged budgets tied to each enforcement phase, and early provisioning for any security amount so that a favourable order is not held up by an inability to post the bond.

What changes in 2026

The enforcement environment in 2026 reflects a heavier tactical reliance on customs measures and earlier, more thorough China-side supply-chain investigation. As cross-border trade with China intensifies, rights holders are front-loading their evidence work, assembling the customs application and injunction papers before infringing shipments materialise, rather than reacting after the fact. The maturing Unified Patent Court is an additional consideration: for European patents without an opt-out, or for patents with unitary effect, the UPC offers a further venue whose interaction with national German proceedings should be assessed for each right.

Practical tips for adapting 2026 strategies

• Coordinate earlier with customs. Register rights and refine technical descriptions well ahead of anticipated shipments so detentions are triggered reliably.
• Invest in China supply-chain intelligence. Trace manufacturers and exporters at the outset, so each detained consignment can be linked to a source and future shipments anticipated.
• Prepare cross-border evidence preservation. Have chain-of-custody protocols and laboratory testing arrangements ready before the ten-working-day customs clock starts.
• Pre-draft injunction papers. Keep supporting statements and patent documentation packaged so filing can follow detention within the statutory window.

Effective pharmaceutical patent enforcement germany in 2026 rewards preparation over reaction. The organisations that succeed are those that treat enforcement as a standing capability, not a one-off project.

Common pitfalls and how to avoid them

• Weak evidence chain. A broken chain of custody can undermine laboratory results and samples. Maintain a rigorous log from the first sample collection.
• Misreading exhaustion. Enforcing against genuine parallel imports lawfully marketed in the EEA invites failure and wrongful-injunction liability. Verify the supply chain first.
• Insufficient product identification. Vague technical descriptions weaken both customs detention and court applications. Provide precise, inspectable identifiers.
• Not planning for security. An injunction can stall if a required bond cannot be posted promptly. Provision for it before filing.
• Failing to coordinate with customs. Missing the statutory window after detention risks release of the goods. Have court papers ready to file in parallel.

Conclusion

Pharmaceutical patent enforcement germany in 2026 is a matter of coordinated speed: the border, the courtroom and the supply-chain investigation must work together, and much of the preparation should be done before the infringing shipment arrives. Confirm enforceability against the exhaustion doctrine, register rights with German customs, assemble an admissible evidence package with proper chain of custody, and keep injunction papers ready to file within the statutory customs window. Executed methodically, this playbook helps stop infringing imports at the border, preserves the damages claim and disrupts the source. For further reading, see Dr. Anke Krebs, profile, and related GLE resources on Pharmaceutical practice in Germany.

Sources

1. Patentgesetz (German Patent Act)
2. Zivilprozessordnung (ZPO), German Code of Civil Procedure
3. Regulation (EU) No 608/2013 on customs enforcement of intellectual property rights
4. Union Customs Code (Regulation (EU) No 952/2013)
5. German Customs (Zoll), official portal, including IPR protection guidance
6. Deutsches Patent- und Markenamt (DPMA), patent information
7. Bundespatentgericht (Federal Patent Court)
8. Bundesgerichtshof (BGH), Federal Court of Justice